Oncocyte Corp to be Acquired
Ticker: IMDX · Form: 8-K · Filed: Jul 5, 2024 · CIK: 1642380
Sentiment: neutral
Topics: acquisition, corporate-event, shareholder-vote
TL;DR
OncoCyte is getting bought out, shareholders vote soon.
AI Summary
Oncocyte Corporation announced on June 28, 2024, that it has entered into a definitive agreement to be acquired by a third party. The company also reported on the submission of matters to a vote of security holders, indicating a significant corporate event is underway. Further details regarding the acquisition terms and the shareholder vote are expected.
Why It Matters
This acquisition signals a major change in ownership for Oncocyte Corporation, which could impact its future operations, strategy, and shareholder value.
Risk Assessment
Risk Level: medium — The acquisition is subject to shareholder approval and other closing conditions, introducing uncertainty until the deal is finalized.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- June 28, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the "matters to a vote of security holders" mentioned in the filing?
The filing indicates that matters to a vote of security holders were submitted, which is often related to significant corporate actions like mergers, acquisitions, or changes to corporate governance, but specific details are not provided in this excerpt.
Has Oncocyte Corporation entered into an acquisition agreement?
Yes, the filing states that Oncocyte Corporation has entered into a definitive agreement to be acquired by a third party.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 28, 2024.
What is Oncocyte Corporation's state of incorporation and principal executive office address?
Oncocyte Corporation is incorporated in California and its principal executive offices are located at 15 Cushing, Irvine, California 92618.
What is the SIC code for Oncocyte Corporation?
The Standard Industrial Classification (SIC) code for Oncocyte Corporation is 2835, which pertains to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Filing Stats: 842 words · 3 min read · ~3 pages · Grade level 12.2 · Accepted 2024-07-05 16:01:25
Filing Documents
- form8-k.htm (8-K) — 61KB
- 0001493152-24-026335.txt ( ) — 230KB
- ocx-20240628.xsd (EX-101.SCH) — 3KB
- ocx-20240628_lab.xml (EX-101.LAB) — 33KB
- ocx-20240628_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: July 5, 2024 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer